Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vaxart Announces Positive Phase 1 Study of Oral Norovirus Vaccine View HTML
Toggle Summary Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir
ATLANTA , Feb. 13, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its Phase 2b SPIRITUS
View HTML
Toggle Summary Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results
Conference Call to be Held Today at 4:30 P.M. ET
View HTML
Toggle Summary Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585
ATLANTA , Feb. 01, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (Nasdaq:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its
View HTML
Toggle Summary Aviragen Therapeutics to Host Conference Call to Report Second Quarter Fiscal Year 2017 Financial Results on February 2, 2017
ATLANTA , Jan. 26, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, February 2, 2017 at 4:30 p.m.
View HTML
Toggle Summary Aviragen Therapeutics to Present at Stifel 2016 Healthcare Conference
ATLANTA , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics , Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that Aviragen's CFO & Executive Vice President Mark Colonnese will present a corporate overview at the Stifel 2016
View HTML
Toggle Summary Aviragen Therapeutics Reports First Quarter Fiscal Year 2017 Financial Results
Conference Call to be Held Today at 4:30 P.M. ET
View HTML
Toggle Summary Aviragen Therapeutics to Host Conference Call to Report First Quarter Fiscal Year 2017 Financial Results on November 3, 2016
ATLANTA , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, November 3, 2016 at 4:30 p.m.
View HTML
Toggle Summary Aviragen Therapeutics to Host KOL Meeting on HRV Infections on October 13, 2016 in New York
ATLANTA , Oct. 10, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, announced today that it will host a Key Opinion Leader (KOL) breakfast focused on the growing burden of human rhinovirus (HRV)
View HTML
Toggle Summary Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2016 Financial Results
Conference Call to be Held Today at 4:30 P.M. ET
View HTML
Toggle Summary Aviragen Therapeutics Announces Rescheduled Date and Time of Fourth Quarter and Fiscal Year 2016 Financial Results on September 14, 2016
ATLANTA , Sept. 13, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Wednesday, September 14, 2016
View HTML
Toggle Summary Aviragen Therapeutics to Present at Upcoming Investor Conferences
ATLANTA , Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, announced today that Aviragen's CEO & President Joseph Patti, PhD will present a corporate
View HTML
Toggle Summary Aviragen Therapeutics Announces Inducement Grant for New Employees
ATLANTA , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, announced today that the Company has granted two new hires options to purchase an aggregate
View HTML
Toggle Summary Aviragen Therapeutics Announces Schedule Change for Fourth Quarter and Fiscal Year End 2016 Financial Results Conference Call and Webcast
ATLANTA , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, announced today that it is delaying the time of its fourth quarter and fiscal year end 2016
View HTML
Toggle Summary Aviragen Therapeutics to Host Conference Call to Report Fourth Quarter and Fiscal Year 2016 Financial Results on September 8, 2016
ATLANTA , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, September 8, 2016
View HTML

Log In

Create an account